|Bid||80.90 x 1800|
|Ask||87.50 x 1400|
|Day's Range||78.26 - 84.64|
|52 Week Range||57.24 - 127.80|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 02, 2010|
|1y Target Est||181.67|
Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) were flat in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share rose 112.24% year over year to $1.04, which beat the estimate of $0.98.Revenue of $41,848,000 up by 68.69% from the same period last year, which missed the estimate of $44,360,000.Outlook The upcoming fiscal year's EPS expected to be between $6.00 and $6.00.The upcoming fiscal year's revenue expected to be between $285,000,000 and $285,000,000.Details Of The Call Date: Oct 30, 2020View more earnings on LGNDTime: 08:30 AMET Webcast URL: https://engage.vevent.com/index.jsp?eid=7772&seid=77/main/simplifyPrice Action Company's 52-week high was at $127.8052-week low: $57.24Price action over last quarter: down 29.55%Company Profile Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For October 30, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.